



Target-Specific Delivery of Gold and Ruthenium Complex to Cancer Cells: Where Are We?

Guest Editors:

Dr. Tânia S. Morais

Centro de Química Estrutural,
Faculdade de Ciências da
Universidade de Lisboa, 1749-016
Lisboa, Portugal

Dr. João D. G. Correia

Departamento de Engenharia e
Ciências Nucleares and Centro
de Ciências e Tecnologias
Nucleares, Instituto Superior
Técnico, Universidade de Lisboa,
CTN, Estrada Nacional 10 (Km
139,7), 2695-066 Bobadela LRS,
Portugal

Deadline for manuscript
submissions:

closed (31 May 2023)

Message from the Guest Editors

Cancer is the second leading cause of death worldwide, and it is expected that in 20 years, there will be ~26 million new cancer cases. Despite the progress made in the last few years, cancer treatment, mainly focused on radiation therapy and chemotherapy, presents low therapeutic indices and a wide spectrum of severe side-effects, in part due to the little or no selectivity of drugs for cancer cells over nontumoral cells. Therefore, the need for alternative therapeutic options with improved selectivity is critical.

Following the clinical success achieved with platinum complexes, the search for metallodrugs with improved therapeutic properties has been extremely active within the bioinorganic/organometallic chemistry community. Among the large number of metal complexes with considerable anticancer properties, gold and ruthenium complexes are amongst the most promising alternatives. Nevertheless, this topic still remains a challenge to all scientists, especially those involved in the design of innovative metal-based target specific agents.

We welcome submissions dealing with advancements and challenges of metallodrug discovery for cancer treatment.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Thomas J. Schmidt

Institute of Pharmaceutical
Biology and Phytochemistry,
University of Münster,
Corrensstrasse 48, D-48149
Münster, Germany

Message from the Editor-in-Chief

As the premier open access journal dedicated to experimental organic chemistry, and now in its 25th year of publication, the papers published in *Molecules* span from classical synthetic methodology to natural product isolation and characterization, as well as physicochemical studies and the applications of these molecules as pharmaceuticals, catalysts and novel materials. Pushing the boundaries of the discipline, we invite papers on multidisciplinary topics bridging biochemistry, biophysics and materials science, as well as timely reviews and topical issues on cutting edge fields in all these areas.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [MEDLINE](#), [PMC](#), [Reaxys](#), [CaPlus / SciFinder](#), [MarinLit](#), [AGRIS](#), and [other databases](#).

Journal Rank: JCR - Q2 (*Chemistry, Multidisciplinary*) / CiteScore - Q1 (*Chemistry (miscellaneous)*)

Contact Us

Molecules Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/molecules
molecules@mdpi.com
[X@Molecules_MDPI](https://twitter.com/X@Molecules_MDPI)